drugset / Trial / NCT04276909

Feasibility Study of LUM Imaging System for Pancreatic Cancer

NCT04276909 ↗

Withdrawn Lumicell, Inc.
NaSingle-groupOpen-labelOther

Summary

This single-site, non-randomized, open-label study to assess the initial safety and efficacy of the LUM Imaging System for detection of primary pancreatic cancer and peritoneal invasion from primary pancreatic cancer during surgery. In this feasibility study, the tumor detection algorithm will be developed for this indication.

Timeline

Start
2026-01
Primary completion
2026-01
Completion
2026-01

Outcome

Outcome not reported

Stopped: “Study not initiated.”

Drugs

EvaluationDrugModalityDoseRoute
Subject PEGULICIANINE ACETATE Diagnostic / imaging agent 1 mg/kg Intravenous